ArticleTransboundary and emerging diseases2022
Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes.
Article in Transboundary and emerging diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 18 citations in OpenAlex.
- Live-Attenuated Rift Valley Fever Virus Vaccination Leads to Durable, Protective Immunity Independent of Sex in C57BL/6 Mice.The Journal of infectious diseases · 2026Article
- Immunopharmacologsical and structural insights into Rift Valley fever virus envelope glycoproteins: an immunoinformatics approach to multi-epitope vaccine design.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Development of a Novel Immune Gene Array to Assess Mosquito Gene Expression During Arbovirus Infection.Viruses · 2026Article
- Identification and mapping of potential and highly likely vectors for selected vector-borne diseases in the EU and neighbouring countries.EFSA journal. European Food Safety Authority · 2026Article
- Article
- Altered histone modifications in Aedes aegypti midguts following Rift Valley fever virus exposure.Scientific reports · 2026Article
- Altered histone modifications inbioRxiv : the preprint server for biology · 2025Article
- Recent advances in treatment and detection of Rift Valley fever virus: a comprehensive overview.Virus genes · 2025Review
- Co-Infection ofViruses · 2025Article
- Review
- Review
- Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates.NPJ vaccines · 2023Review
- Article
- Rift Valley Fever Virus Primes Immune Responses inPathogens (Basel, Switzerland) · 2023Article
- Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use.Vaccines · 2023Review
- Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses.Frontiers in cellular and infection microbiology · 2023Review
- Replication Kinetics of a Candidate Live-Attenuated Vaccine for Cache Valley Virus inVector borne and zoonotic diseases (Larchmont, N.Y.) · 2022Article
- Review
- Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models.NPJ vaccines · 2022Article
- Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes.Transboundary and emerging diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rift Valley fever virus (RVFV) is a mosquito-borne pathogen with significant human and veterinary health consequences that periodically emerges in epizootics. RVFV causes fetal loss and death in ruminants and in humans can lead to liver and renal disease, delayed-onset encephalitis, retinitis, and in some cases severe haemorrhagic fever. A live attenuated vaccine candidate (DDVax), was developed by the deletion of the virulence factors NSs and NSm from a clinical isolate, ZH501, and has proven safe and immunogenic in rodents, pregnant sheep and non-human primates. Deletion of NSm also severely restricted mosquito midgut infection and inhibited vector-borne transmission. To demonstrate environmental safety, this study investigated the replication, dissemination and transmission efficiency of DDVax in mosquitoes following oral exposure compared to RVFV strains MP-12 and ZH501. Infection and dissemination profiles were also measured in mosquitoes 7 days after they fed on goats inoculated with DDvax or MP-12. We hypothesized that DDVax would infect mosquitoes at significantly lower rates than other RVFV strains and, due to lack of NSm, be transmission incompetent. Exposure of Ae. aegypti and Cx. tarsalis to 8 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.